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Chordoma is a malignant tumour derived from 
remnants of the fetal notochord; it occurs along the 
spinal axis, predominantly in the sphenooccipital 
(35%), vertebral (15%) and sacrococcygeal (50%) 
regions. 
Clinics and pathology 
Etiology 
Although most chordomas are sporadics, five 
families with chordoma occurrence have been 
reported, two of them displaying an autosomal 
dominant transmission with incomplete penetrance 
(MIM. *215400); preliminary linkage data in a 
three generation family suggest that the disease 
locus might be assigned to chromosomes 1,17 or 
19. 
Epidemiology 
Chordomas accounts for 1-4% of all primary bone 
tumours; the sacrococcygeal lesions are more 
common in the fifth decade of life, whereas the 
sphenooccipital tumours occur predominantly in 
children. 
Clinics 
Chordoma is a slowly-growing tumour, 
characterized by local destruction of bone and 
rarely distant metastatic spread. 
The differential diagnosis includes renal tumours, 
chondrosarcomas and myxo-papillary 
ependymoma. 
Pathology 
Microscopically, it resembles normal fetal 
notochord in its different stages of development; it 
is composed of extremly large cells (know as 
physaliferous) and other small tumour cells; areas 
of cartilage and bone may be present. 
Cytogenetics 
Cytogenetics Morphological 
In eight sporadic sacral chordomas with abnormal 
karyotype, a tumour-specific rearrangement has not 
been identified; the karyotypes, characterized by a 
hypo-or near-diploid chromosome number, showed 
complex rearrangements affecting several 
chromosomes, among them chromosome 1 was 
frequently involved in losses and translocations 
with different partners; no FISH experiments to 
clarify the complex cytogenetic picture have been 
performed so far. 
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